Literature DB >> 11821078

Use of recombinant human follicle-stimulating hormone in the treatment of male factor infertility.

Carlo Foresta1, Andrea Bettella, Maurizio Merico, Andrea Garolla, Alberto Ferlin, Marco Rossato.   

Abstract

OBJECTIVE: To evaluate the effects of treatment with recombinant human FSH (r-hFSH) on seminal parameters and seminiferous epithelium in idiopathic patients with oligozoospermia with normal FSH plasma levels.
DESIGN: Randomized single-blind study.
SETTING: Academic setting. PATIENT(S): Forty-five subjects with idiopathic oligozoospermia (sperm count <10 x 10(6)/mL) and normal FSH and inhibin B plasma levels. INTERVENTION(S): Three months of treatment with r-hFSH 50 IU (15 patients) or with r-hFSH 100 IU on alternate days (15 patients) or no treatment (15 patients); bilateral testicular fine-needle aspiration (FNA) performed before and after therapy; FSH and inhibin B plasma levels evaluated during treatment. MAIN OUTCOME MEASURE(S): Seminal parameters; testicular cytological features evaluated by FNA; plasma levels of FSH, LH, T, and inhibin B. RESULT(S): Treatment with r-hFSH at a dose of 50 IU induced no increase in sperm concentration, while treatment with r-hFSH at a dose of 100 IU induced a significant increase in sperm concentration. In particular, in 11/15 patients a doubling of the pretreatment sperm concentration was observed. No significant increase in sperm parameters was observed in the control group. In both groups of patients treated with r-hFSH, the cytological analysis before treatment showed hypospermatogenesis. An increase in the percentage of spermatogonia and spermatocytes was observed only after the treatment with r-hFSH at a dose of 100 IU. CONCLUSION(S): The findings of this study demonstrate that r-hFSH at a dose of 100 IU, as previously seen with highly purified FSH, increases the spermatogonial population and sperm production in idiopathic patients with oligozoospermia with normal FSH and inhibin B plasma levels and a cytological picture of hypospermatogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11821078     DOI: 10.1016/s0015-0282(01)02966-1

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  15 in total

Review 1.  Management strategies for male factor infertility.

Authors:  Gerhard Haidl
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  The use of follicle stimulating hormone (FSH) for the treatment of the infertile man: position statement from the Italian Society of Andrology and Sexual Medicine (SIAMS).

Authors:  A Barbonetti; A E Calogero; G Balercia; A Garolla; C Krausz; S La Vignera; F Lombardo; E A Jannini; M Maggi; A Lenzi; C Foresta; A Ferlin
Journal:  J Endocrinol Invest       Date:  2018-02-01       Impact factor: 4.256

3.  Effects of highly purified follicle-stimulating hormone on sperm DNA damage in men with male idiopathic subfertility: a pilot study.

Authors:  S Palomba; A Falbo; S Espinola; M Rocca; S Capasso; F Cappiello; F Zullo
Journal:  J Endocrinol Invest       Date:  2011-05-23       Impact factor: 4.256

4.  Hormonal control of inhibin B in men.

Authors:  V A Giagulli; D Carbone
Journal:  J Endocrinol Invest       Date:  2006-09       Impact factor: 4.256

Review 5.  Follicle-stimulating hormone treatment in normogonadotropic infertile men.

Authors:  Daniela Valenti; Sandro La Vignera; Rosita A Condorelli; Rocco Rago; Nunziata Barone; Enzo Vicari; Aldo E Calogero
Journal:  Nat Rev Urol       Date:  2012-12-11       Impact factor: 14.432

Review 6.  FSH treatment of male idiopathic infertility improves pregnancy rate: a meta-analysis.

Authors:  D Santi; A R M Granata; M Simoni
Journal:  Endocr Connect       Date:  2015-06-25       Impact factor: 3.335

7.  FSH dosage effect on conventional sperm parameters: a meta-analysis of randomized controlled studies.

Authors:  Rossella Cannarella; Sandro La Vignera; Rosita A Condorelli; Laura M Mongioì; Aldo E Calogero
Journal:  Asian J Androl       Date:  2020 May-Jun       Impact factor: 3.285

8.  Deficiency of TPPP2, a factor linked to oligoasthenozoospermia, causes subfertility in male mice.

Authors:  Feng Zhu; Peipei Yan; Jingjing Zhang; Yiqiang Cui; Meimei Zheng; Yiwei Cheng; Yueshuai Guo; Xiaoyu Yang; Xuejiang Guo; Hui Zhu
Journal:  J Cell Mol Med       Date:  2019-01-24       Impact factor: 5.310

Review 9.  Follicle-stimulating Hormone (FSH) Action on Spermatogenesis: A Focus on Physiological and Therapeutic Roles.

Authors:  Daniele Santi; Pascale Crépieux; Eric Reiter; Giorgia Spaggiari; Giulia Brigante; Livio Casarini; Vincenzo Rochira; Manuela Simoni
Journal:  J Clin Med       Date:  2020-04-03       Impact factor: 4.241

10.  An Integrated Analysis of Network Pharmacology, Molecular Docking, and Experiment Validation to Explore the New Candidate Active Component and Mechanism of Cuscutae Semen-Mori Fructus Coupled-Herbs in Treating Oligoasthenozoospermia.

Authors:  Xue Bai; Yibo Tang; Qiang Li; Dan Liu; Guimin Liu; Xiaolei Fan; Zhejun Liu; Shujun Yu; Tian Tang; Shuyan Wang; Lingru Li; Kailin Zhou; Yanfei Zheng; Zhenquan Liu
Journal:  Drug Des Devel Ther       Date:  2021-05-17       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.